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Scope: Green leafy vegetables (GLV) may improve postprandial glycemic
responses (PGR) and metabolic health. However, inter-individual variations
(IIV) preclude conclusive evidence. Sirtuin system is emerging as a key player
in blood glucose control. This study investigates IIV in PGR in women
co-ingesting GLV with a carbohydrate meal and interactions with the sirtuin
system.
Methods and Results: Volunteers (n = 31 women) consume rice, rice with
bok choy, or spinach (75g available carbohydrate) on separate occasions.
Postprandial glucose, insulin, adropin, and lipid levels are measured.
Anthropometric measurements and sex hormones are measured. GeXP assay
measures whole blood postprandial gene expression profiles of 25 markers
involved in sirtuin signaling. GLV consumption has no significant effect on
PGR, which shows high variation. PGR correlated with age, but no other
consistent associations are observed. Sirtuin gene expression profiles reveal
distinct stratified subgroups associated with PGR, lipid, insulin, fat mass,
waist/hip circumferences, and adropin levels.
Conclusion: PGR to co-ingesting GLV with a carbohydrate meal are highly
variable in this cohort and fail to reveal a significant reduction in PGR.
Variable responses are largely independent of menopausal status and meal
consumed. However, lower expression of sirtuin gene targets is associated
with higher PGR and with markers linked to health status.
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1. Introduction
Postprandial glycemia is an important in-
dicator ofmetabolic health and a driver of
chronic diseases such as cardiovascular
disease (CVD) and type 2 diabetes mel-
litus (T2D). Despite interventions, inci-
dence of these diseases is increasing with
annual global CVD mortality currently at
17.9 million[1] and T2D prevalence at 425
million.[2] Further research is required
to achieve global reversal targets.[3] Post-
prandial hyperglycemia, is a critical factor
for optimizing glycemic control[4] with
individuals spending most of their day in
a postprandial state. Studies indicate lin-
ear relationships between postprandial
glucose concentrations and CVD in in-
dividuals with normal fasting glucose[5,6]
suggesting increasing postprandial glu-
cose increases CVD risk.[7] However,
many of these studies are confounded
by inter-individual variation (IIV) in
postprandial glycemic responses (PGR)
which preclude firm conclusive evidence.
Possible factors responsible for these
variations include genetics,[8] biological
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sex,[9,10] menopausal status,[11] age[8,9] and insulin sensitivity.[12]
Hormones such as adropin are also implicated in the regulation
of metabolic health,[13] glucose regulation, and CVD.[14]
Studies report that pre-menopausal women have a lower
incidence of CVD compared to men of same age, attributed
partly to physiological estrogen levels.[15] However, obesity and
its associated abnormalities could reverse these protective ef-
fects leading to increased CVD risk even in pre-menopausal
women. The risk of CVD rapidly increases after menopause,[16]
and by age 70, women show CVD rates similar to that of
men.[17]
The quantity and quality of carbohydrate consumed is a
major predictor of PGR.[18] Non-carbohydrate dietary con-
stituents could reduce PGR in healthy and diabetic individuals,
particularly green leafy vegetables (GLV).[19–22] Acute phase inves-
tigators, however, have reported mixed results, potentially due to
IIV in PGR among healthy adults.[23,24] Sun et al. concluded that
co-ingesting bok choy with rice, attenuated participants’ PGR.[30]
However, IIV was highlighted in their responses, demonstrating
both sex specific (slower postprandial blood glucose reduction
in women) and within sex IIV in PGR.[10] Research implies that
multiple factors influence PGR. However, limited work has been
carried out to elucidate reasons for these variations particularly
in pre-, peri-, and post-menopausal women.
Previous studies in our lab have used blood gene expression
profiling as a means of investigating IIV in metabolic responses
to interventions.[25,28,34] Gene expression profiling technologies
present opportunities to gain an insight on outputs from the
human genome, permitting investigation of IIV in response to
diet and associated influences on health and prevention of nu-
trition associated chronic diseases.[34] Studies identified variable
levels of SIRT1 in whole blood from apparently healthy hu-
man participants.[25] Further interrogation revealed that partic-
ipants with low SIRT1 expression, had poorer metabolic profiles
with higher levels of plasma inflammatory markers, deregulated
metabolic responses to food consumption and low levels of HDL,
markers implying compromised metabolic health status.[25] No-
tably, this revealed that whole blood gene expression profiles can
be used to characterize individual responses to dietary interven-
tion.
Sirtuins and associated genes involved in producing the chem-
ical nicotinamide adenine dinucleotide (NAD) play a pivotal role
in aging-related metabolic diseases, in metabolic health, and glu-
cose homeostasis.[25,26] Reduced sirtuin expression due to obesity
and ageing is correlated with T2D pathogenesis[27] and sex differ-
ences are apparent.[28] The sirtuin/NAD system is also reported
to be differentially regulated in response to glucose intolerance
during consumption of a high fat diet.[25]
This study hypothesized that co-ingesting GLV with carbo-
hydrates would not significantly reduce PGR due to IIV in re-
sponses and that IIV would be associated with sirtuin gene ex-
pression signatures. With much of the prevailing research on
PGR excluding females due to perceived complications linked to
menstruation,[29] this study aimed to investigate IIV in PGR in
women co-ingesting GLV with a carbohydrate meal. The study
also aimed to determine whether these IIV were associated with
modulation of the sirtuin system.
2. Experimental Section
2.1. Study Population and Design
VegGI (Impact of Vegetables on Acute Glycemia and Glycemia-
Induced CVD risk in women: metabolic effects and IIV) study
was a randomized controlled crossover study to assess the acute
effects of consuming GLV on PGR in women (Figure 1A,B). In-
clusion criteria included written informed consent, females aged
between 18 and 75 years, BMI in the range of 25–35 kg m−²,
HbA1c < 6.5%, total cholesterol < 5 mmol L−1, systolic blood
pressure (BP) < 139 mmHg and diastolic BP < 89 mmHg, no
chronic health conditions. Smokers, athletes, those with food
intolerances, eating disorders, pregnant or breastfeeding, using
prescription medication including hormonal contraceptives, thy-
roid medications, or hormonal replacement therapy were ex-
cluded.
The study recruited 31 participants between July 2017 and June
2019. Power calculations based on effect sizes seen in Sun et al.[30]
showed 10 women were adequate to give the study 90% power
to detect differences in blood glucose (measured as incremental
area under the curve: iAUC for 180 min) of about 20% in mag-
nitude. Therefore, the number used for the study was enough to
detect treatment effects and study IIV. The study was conducted
in accordance with the Declaration of Helsinki and approved by
the Ethics Committee of the Rowett Institute. VegGI study is reg-
istered at Research Registry (researchregistry3117).
Participants were provided a standardized meal the evening
prior to all sessions, consisting of a vegetarian paella (made in-
house), a soft white roll (big bite soft white roll, Tesco, UK) and a
toffee yoghurt (Muller Light Smooth Toffee Yoghurt, Tesco, UK).
They attended the Human Nutrition Unit (HNU) at the Rowett
Institute in the morning after an overnight fast having avoided
strenuous exercise and alcohol for 24 h. Menopausal status was
assessed, where pre-menopause was defined as currently men-
struating; peri-menopause as experiencing noticeable changes
in the length, duration, or amount of flow in the menstrual cy-
cle; and post-menopause as not having a menstrual cycle in the
last 12 months (not due to hormonal contraceptives).[31] Pre-
menopausal women attended the visits during the luteal phase
to minimize sex hormone variations.
2.2. Interventions and Sample Collection
A glucose drink was prepared using 75 g of anhydrous glucose
(Bulk Powders, UK) dissolved in 300 mL of water (room temper-
ature) and consumed prior to oral glucose tolerance test (OGTT).
Food-based interventions were as follows: white boiled rice (R),
white rice with bok choy (RB), and white rice with spinach (RS)
(Figure 1A). A portion of R (Thai Fragrant Rice, Sainsbury’s UK)
was defined as the amount containing 75 g of available carbohy-
drate and was boiled in water. Bok choy (Bok Choy, Tesco, UK)
and spinach (Baby Spinach, Tesco, UK) consisted of a fresh por-
tion size of 150 g and steamed for 25 and 10min, respectively, and
pureed before serving. Volunteers were instructed to eat half the
portion of GLV provided and then consume the rice and vegetable
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Figure 1. VegGI study overview and flow chart. A) An overview of the study involvement for each participant. Participants completed OGTT session and
then randomly were assigned to consume each of the intervention meals, R, RB, and RS. B) VegGI recruitment and retention. CGM, continuous glucose
monitoring system; GeXP, gene expression; OGTT, oral glucose tolerance test; R, rice; RB, rice with bok choy; RS, rice with spinach; § completed in all
sessions; ● completed in R, RB, and RS; ○ completed in OGTT.
interchangeably within 15 min and the glucose drink within
5 min. Compositional information for the food-based interven-
tions can be found in the Table S1, Supporting Information.
During the first study session (OGTT), participant anthro-
pometric measurements (weight, waist and hip circumference,
and body fat composition using BODPOD) were collected. Base-
line blood samples were collected to determine fasting glucose
and insulin levels and an OGTT was completed following WHO
Guidelines.[32] A cannula was inserted into the antecubital fossa
in either the left or right arm and kept patent with sterile saline
(0.9% NaCl). Venous blood samples were collected at baseline
and at 15 min, 30 min, 45 min, 1 h, 1.5 h, and 2 h postprandi-
ally into 3 mL EDTA plasma tubes (Becton Dickinson, USA) and
at 30 min, 1 h, and 2 h into PaxGene tubes (PreAnalytiX). Blood
samples were also collected into a 4mL serum tube (BectonDick-
inson, USA) for sex hormones analysis (Figure 1A).
Participants were randomly assigned to consume each of
the intervention meals, R, RB, and RS during the course of
three visits. Blood glucose levels for these intervention visits
were measured using a continuous glucose monitoring system
(CGM) (iPro2, Medtronic MiniMed, Northridge, USA), which
measured interstitial glucose concentrations every 5 min giving
48 data points per treatment per volunteer. CGM was fitted the
day prior to interventions and worn for approximately 24 h.
The monitor was calibrated using finger prick blood samples
analyzed by a glucose meter (Bayer Contour NEXT, Ascensia
Diabetes Care, USA). Blood samples were collected as shown
in Figure 1A. Four hours after the test meal was consumed, the
cannula was removed (Figure 1A).
Plasma and serum were prepared by centrifugation at
3000 rpm, 4 °C for 15 min (Fisherbrand GT2 Benchtop Cen-
trifuge Packs, Fisher Scientific, UK), aliquoted, and stored at−70
°C. Insulin, adropin, lipids, and sex hormone analysis were mea-
sured as described below. Blood collected in PaxGene tubes were
stored according to the manufacturer’s instructions prior to total
RNA extraction (see below).
2.3. Plasma Analyses
Glucose levels duringOGTTweremeasured using theHemoCue
201 Glucose Analyser (HemoCue AB, Sweden). Plasma insulin
was measured using a two-site enzyme immunoassay kit
(Mercodia human insulin ELISA, Uppsala, Sweden). iAUC
was calculated for both insulin and glucose levels after inter-
vention using the trapezoid rule.[33] Sex hormones, estradiol,
progesterone, follicular stimulating hormone (FSH), and testos-
terone were measured in serum using an immunoassay system
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(ADVIA Centaur XPT, Siemens Healthcare Ltd, UK). An ELISA
kit (Cusabio USA) was used to measure plasma adropin. Lipid
profiles were quantified in plasma samples using a Thermo
Konelab clinical analyser (Thermo Electron Oy, Vantaa, Fin-
land) and kits for HDL, LDL, total cholesterol, and triglycerides
(Microgenics GmbH Passau, Germany).
2.4. Blood Expression Profiling of Sirtuin and NAD Biosynthetic
Enzyme Genes
Total RNA was extracted from human whole blood samples
using a PAXgene Blood RNA Kit (Qiagen, Crawley, UK) and
50 ng was assayed for sirtuin and NAD biosynthetic enzyme
gene targets using the GenomeLab GeXP Genetic Analysis
System (Beckman Coulter) and an in-house custom designed
assay, the hSIRTNADPlex as described previously.[28] Details
of the GenomeLab System for design of in-house custom de-
signed multiplex assays and application to conduct blood gene
expression profiling have been published previously.[25,28,34]
2.5. Statistical Analysis
Postprandial glucose and insulin responses were expressed as
iAUC ignoring the area below the baseline. Glucose, insulin,
and sex hormones were analyzed using linear mixed models
where meals and menopausal status were fixed factors and vol-
unteer was a random factor. Lipid profiles and adropin levels
were analyzed using three-way mixed ANOVA with meals and
time point used as within-subject factors and menopausal sta-
tus as between-subject factor. Post hoc tests were performed to
check for significant differences using Bonferroni adjustment.
Pearson correlations were calculated to assess potential associa-
tions between PGR and metabolic, anthropometric, and gene ex-
pression dataset. Principal component analysis (PCA) and partial
least squares (PLS) were performed on the hSIRTNAD gene ex-
pression (Y) dataset, and metabolic (fasting glucose, glucose and
insulin iAUC, plasma lipid, adropin levels) and anthropometric
markers (fat mass, waist and hip circumference, waist-to-hip ra-
tio) (X) using SIMCA-P+ 14.1 software (MKS Instruments UK
Ltd.). The assumptions of the statistical test have been assessed
and deviations were not substantial.
3. Results
3.1. Study Participant Anthropometric Data
Thirty-one women were recruited to the VegGI study and com-
pleted the four study sessions (10 pre-menopausal, 3 peri-
menopausal, and 18 post-menopausal). The mean ± SD age was
51.3 ± 14.8 years, height 1.63 ± 0.08 m, weight 73.9 ± 7.7 kg, and
BMI 27.9 ± 1.6 kg m−2. Baseline anthropometric measures are
shown in Table 1.
3.2. Postprandial Glucose and Insulin Responses to GLV
Due to CGM technical issues, PGR was measured on 29 partic-
ipants in R visit (10 pre-menopausal, 2 peri-menopausal, and 17
Table 1. Baseline anthropometric and plasma characteristics of the study
population.
All participants (n = 31)
Age [years] 51.3 ± 14.8 (20–70)
Height [m] 1.6 ± 0.1 (1.5–1.8)
Weight [kg] 73.9 ± 7.7 (59.9–86.7)
BMI [kg m−2] 27.9 ± 1.6 (24.8–30.5)
Total cholesterol [mmol L−1] 5.4 ± 1.1 (3.0–7.0)
HbA1c [%] 5.3 ± 0.3 (4.8–5.8)
Systolic BP [mmHg] 125.4 ± 17.5 (95–171)
Diastolic BP [mmHg] 74.3 ± 8.4 (60–92)
Fat mass [%] 39.1 ± 6.8 (26.1–56.6)
Waist circumference [cm] 85.9 ± 5.7 (75.4–94)
Hip circumference [cm] 103.8 ± 6.8 (77.5–114.9)
Waist:hip 0.8 ± 0.1 (0.7–1.1)
Fasted glucose OGTT [mmol L−1] 4.8 ± 0.9 (3.8–8.3)
Fasted glucose R [mmol L−1] 5.3 ± 0.7 (3.4–6.9)
Fasted glucose RB [mmol L−1] 5.4 ± 0.7 (3.5–6.6)
Fasted glucose RS [mmol L−1] 5.5 ± 0.8 (3.3–6.7)
Fasted total cholesterol R [mmol L−1] 4.6 ± 0.8 (3.2–5.8)
Fasted total cholesterol RB [mmol L−1] 4.8 ± 1.1 (3.0–7.1)
Fasted total cholesterol RS [mmol L−1] 4.7 ± 0.9 (3.1–6.9)
Fasted HDL R [mmol L−1] 1.4 ± 0.4 (0.8–2.1)
Fasted HDL RB [mmol L−1] 1.4 ± 0.4 (0.8–2.2)
Fasted HDL RS [mmol L−1] 1.4 ± 0.3 (0.9–2.2)
Fasted LDL R [mmol L−1] 2.6 ± 0.7 (1.4–4.3)
Fasted LDL RB [mmol L−1] 2.7 ± 0.8 (1.5–4.2)
Fasted LDL RS [mmol L−1] 2.8 ± 0.8 (1.5–4.6)
Fasted TRG R [mmol L−1] 1.2 ± 0.5 (0.4–2.4)
Fasted TRG RB [mmol L−1] 1.3 ± 0.5 (0.5–2.8)
Fasted TRG RS [mmol L−1] 1.2 ± 0.5 (0.6–2.4)
Fasted adropin R [ng mL−1] 1.3 ± 0.7 (0.2–2.9)
Fasted adropin RB [ng mL−1] 1.4 ± 0.6 (0.2–3.5)
Fasted adropin RS [ng mL−1] 1.3 ± 0.7 (0.3–3.4)
Fasted adropin OGTT [ng mL−1] 1.5 ± 0.8 (0.3–3.6)
Data presented as mean ± SD (range); BP, blood pressure; OGTT, oral glucose tol-
erance test; R, rice; RB, rice with bok choy; RS, rice with spinach; TRG, triglyceride.
post-menopausal), on 28 participants in RB (10 pre-menopausal,
3 peri-menopausal, and 15 post-menopausal), and on 28 in RS (8
pre-menopausal, 2 peri-menopausal, and 18 post-menopausal).
Mean postprandial plasma glucose and insulin changes from
baseline during the 4 h postprandial period for the three in-
tervention sessions are shown in Figure 2A,B. There were no
significant differences in glucose iAUC in the study cohort in
response to R (175.8 ± 107.6 mmol × min L−1 0–240 min), RB
(182.8 ± 130.9 mmol × min L−1 0–240 min) or RS (171.7 ±
127.3 mmol × min L−1 0–240 min) (p = 0.487) (Table 2). Like-
wise, there were no significant differences in insulin iAUC in
response to R (4143.3 ± 2544.7 mmol ×min L−1 0–240 min), RB
(3476.8 ± 2415.6 mmol × min L−1 0–240 min), or RS (3870.0 ±
2699.5 mmol × min L−1 0–240 min) (p = 0.104) (Table 2).
Postprandial glucose and insulin were then assessed separately
in the three menopausal groups (Figure 2C–H). No significant
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Figure 2. Postprandial plasma glucose responses using continuous glucose readings from CGM and insulin responses to R, RB, and RS. Mean change
in A) blood glucose using CGM monitor and B) insulin responses in all participants. Mean change in blood glucose using CGM in C) pre-menopausal
(R, RB n = 10, RS n = 8), D) peri-menopausal (R, RS n = 2, RB n = 3), and E) post-menopausal (R n = 17, RB n = 15, RS n = 18) women and in insulin
responses in F) pre-menopausal, G) peri-menopausal, and H) post-menopausal women. Data presented as mean ± SD. Linear mixed model analysis
was used on mean levels at a significance level of p < 0.05 using meal and menopausal status as fixed factors and volunteers as random factor. CGM,
continuous glucose monitor; iAUC; incremental area under the curve; R, rice; RB, rice with bok choy; RS, rice with spinach.
interaction effects on glucose iAUC were found between the
three intervention sessions and menopausal status (p = 0.140)
(Table 2). There was no significant menopausal status effect
or meal × menopausal status interaction for insulin (Table 2).
However, marked IIV was observed within the three menopausal
groups for both glucose and insulin iAUC in response to all
test meals (Figure 3A,B). Postprandial glucose responses sig-
nificantly and positively correlated with age (r = 0.39–0.44, p <
0.05). No other consistent correlations were observed for PGR.
3.3. Sex Hormones
Sex hormone concentrations were measured at each study visit
prior to each test meal (0 h). This confirmed significantly
higher FSH and lower estradiol in post-menopausal women
(Table 3). There was no consistent significant association be-
tween menopausal status and PGR.
3.4. Lipid Profiling
Mean postprandial lipids for all participants following the three
interventions are summarized (Table S2, Supporting Informa-
tion). Repeated measures ANOVA confirmed significant time (p
≤ 0.001) and time × meal (p = 0.034) effects for cholesterol lev-
els. Cholesterol levels between the meals appeared to increase
from 1 to 4 h (Table S2, Supporting Information). A significant
time effect (p ≤ 0.001) for HDL, LDL, and triglyceride levels was
observed with no other significant interaction effects (Table S2,
Supporting Information).
3.5. Adropin
There was no statistically significant interaction between inter-
vention meals and time on plasma adropin in the cohort (p =
0.950). However, there was a time ×meal interaction (p = 0.041)
and time effect (p < 0.001) (Figure 4). Post hoc Bonferroni cor-
rection applied indicated that OGTT resulted in higher average
adropin levels compared to R (1.37 ± 0.07 ng mL−1 and 1.21 ±
0.06 ng mL−1, respectively) but not compared to RB (1.21 ±
0.08 ng mL−1) and RS (1.22 ± 0.06 ng mL−1).
3.6. Sirtuin System Gene Expression Profiling
The hSIRTNADPlex gene expression profiles were mea-
sured at baseline and postprandial time points 30 min, 1 h,
and 2 h in all study sessions using whole blood total RNA

















































































































































































































































































































































































































































































































(RIN values 5.2–8.9). Gene expression was normalized using
ubiquitin-conjugating enzyme E2 D2 (UBE2D2) as Normfinder
(https://moma.dk/normfinder-software)[35] analysis of the
hSIRTNADPlex gene expression data indicated that UBE2D2
exhibited stable expression in the blood samples. Several sir-
tuin system gene responses revealed significant changes in
expression when determined using linear mixed model analysis
with meal (OGTT, R, RB, and RS), time, and meal × time
interactions assigned as fixed factors. HIC1 expression levels
remained skewed following log transformation of the data and
were excluded from further statistical analysis.
Sixteen genes altered significantly post-consumption of the
meals with increased (SIRT1, SIRT2, SIRT3, SIRT6, SIRT7,
NMRK1, NAMPT, PNP, and ABCA1) or decreased expression
(SIRT4, SIRT5, NMNAT3, PARP1, PPIB, NMNAT1, and QPRT)
(Figure S1, Supporting Information). Responses to meals were
significantly different for nine sirtuin genes (SIRT2, SIRT3,
SIRT6, SIRT7, NMNAT3, PNP, PPIB, NAMPT, and PARP1).
However, changes in relevant expression were small (Figure
S1, Supporting Information). Comparison of pre- and post-
menopausal groups using repeated measures ANOVA revealed
significant differences only in the expression levels of NAMPT,
which showed a time ×meal ×menopausal status interaction (p
= 0.014) with no other significant effects (Figure S2, Supporting
Information).
PCA biplot was applied to identify patterns that could be
linked to variable PGR. PCA was conducted on the entire hSIRT-
NAD gene expression dataset (excluding HIC1) to determine
associations between the sirtuin system and PGR variation
(Figure 5A,B). The first two PCA components accounted for
46.2% of the dataset variation (Figure 5A,B). This variation did
not seem to be explained by the menopausal status (Figure 5A)
nor by themeal consumed (Figure 5B). The PCA biplot identified
that the participants located on the right side of the central verti-
cal axis of the plot (subsequently termed subgroup A) exhibited
higher expression of the sirtuin system genes. Further analysis of
gene expression data using repeated measures ANOVA, showed
genemarkers SIRT2, SIRT3, SIRT6, ABCA1, PARP1, PPIB, NM-
NAT1, SIRT1, NADSYN1 (all p < 0.001), NMRK1 (p = 0.009),
NAMPT (p = 0.001), and SIRT5 (p = 0.010) (Supporting Infor-
mation S3) were significantly differently expressed in subgroups
A and B, indicating these genes contributed to stratification of the
cohort. However, most of the anthropometric and plasma base-
line characteristics for subgroups A and B did not demonstrate
any significant differences (Table S3, Supporting Information).
PLS analysis was conducted on the hSIRTNAD gene ex-
pression dataset, and metabolic and anthropometric markers
(X) to identify factors associated with the observed variation of
the sirtuin system in the cohort (Figure 5C,D) and PGR. The
PLS plot revealed that subgroup B was associated with higher
baseline glucose levels, iAUC for glucose and insulin, higher
waist and hip circumference, fat mass percentage, and triglyc-
eride level. In addition, these individuals seemed to have lower
adropin and HDL levels. This association was not associated
with menopausal status (Figure 4C) nor by the meal consumed
(Figure 4D). Notably, correlation analysis also revealed a positive
association between HDL and adropin in the pre-menopausal
women but not in the whole cohort or in the post-menopausal
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Figure 3. Mean and individual postprandial glucose and insulin responses to R, RB, and RS. A) Sum and mean (±SD) iAUC for blood glucose using
CGMmonitor in pre-menopausal (black diamond) (R, RB n = 10, RS n = 8), peri-menopausal (gray circle) (R, RS n = 2, RB n = 3), and post-menopausal
(gray open diamond) (R n = 17, RB n = 15, RS n = 18) and B) sum and mean (n = 31) ± SD iAUC for insulin levels in pre-menopausal (black diamond),
peri-menopausal (gray circle), and post-menopausal women (gray open diamond) following consumption of R, RB, and RS. CGM, continuous glucose
monitor; iAUC; incremental area under the curve; R, rice; RB, rice with bok choy; RS, rice with spinach.
Table 3. Plasma sex hormone concentrations in each menopausal group across all interventions.
Pre-menopausal Peri-menopausal Post-menopausal
FSH [IU L−1] OGTT 8.7 ± 8.8a 37.4 ± 57.2a 78.3 ± 26.2b
R 5.1 ± 2.1a 24.6 ± 21.9a 78.2 ± 27.3b
RB 5.5 ± 3.4a 41.6 ± 46.3a,b 77.4 ± 25.3b
RS 4.5 ± 3a 58.4 ± 51.3b 80.6 ± 24.7b
Estradiol [nmol L−1] OGTT 0.7 ± 0.3a 0.5 ± 0.4a 0.09 ± 0.07b
R 0.4 ± 0.2a 0.4 ± 0.4a,b 0.09 ± 0.1b
RB 0.6 ± 0.5a 0.4 ± 0.3a,b 0.08 ± 0.07b
RS 0.4 ± 0.2a 0.2 ± 0.2a,b 0.09 ± 0.1b
Progesterone [nmol L−1] OGTT 18.7 ± 25.3a 19.7 ± 32.1a 1.4 ± 2.9b
R 13 ± 12.9a 11.8 ± 18a,b 0.7 ± 0.6b
RB 11.1 ± 11.7 11.4 ± 17.4 0.7 ± 0.6
RS 18.4 ± 20.0a 11.3 ± 17.2a,b 0.9 ± 0.7b
Testosterone [nmol L−1] OGTT 1.1 ± 0.2 1 ± 0.1 0.8 ± 0.5
R 0.9 ± 0.3 0.9 ± 0.1 0.7 ± 0.3
RB 1.0 ± 0.3 0.9 ± 0.02 0.7 ± 0.3
RS 0.9 ± 0.2 0.9 ± 0.2 0.8 ± 0.3
Data presented as mean ± SD; Linear mixed model analysis at a significance level of p < 0.05 using meal and menopausal status as fixed factors and volunteers as random
factors; Post hoc analysis were done by pairwise comparison; Different superscript letters indicate significant differences between the means across the menopausal groups
within each visit; FSH, follicle stimulating hormone; OGTT, oral glucose tolerance test; R, rice; RB, rice with bok choy; RS, rice with spin.
women. However, a degree of IIV was still apparent within
subgroups A and B (Figure 5A–D).
4. Discussion
The findings from this study did not provide conclusive evidence
on GLV reducing acute phase glycemia within the specific study
parameters. Based on other studies,[19–22] there could be benefi-
cial effects of GLV on glycemia, perhaps in the long term, when
other types of GLV are given, or when quantities and method of
preparation are changed. Indeed, this supports why some stud-
ies that gave GLV whole saw effects whilst we did not when given
pureed. However, there was notable IIV in PGR, suggestingmul-
tiple factors in addition to meal composition influencing PGR.
Studies report inter- and intra-individual variations between 25%
and 56% in subjects consuming identical test meals.[23,36,37] Indi-
vidual genetics may be a factor determining individual responses
to diet and the sirtuin/NAD systemwas investigated to determine
associations with the observed PGR variations.
The sirtuin system consists of seven sirtuin genes (SIRT 1–
7) and genes encoding enzymes that are involved in the de novo
synthesis of NAD from dietary tryptophan and vitamin B3. In ad-
dition, several enzymes are involved in recycling NAD to regulate
sirtuin activity tomaintain homeostasis and respond tometabolic
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Figure 4. Plasma postprandial adropin levels. Mean ± SD change from
baseline plasma adropin levels in response to R (black line), RB (gray
line), RS (gray dotted line), andOGTT (black dotted line) in all participants
(n = 31). Repeated measures ANOVA were used at a significance level of
p < 0.05. OGTT, oral glucose tolerance test; R, rice; RB, rice with bok choy;
RS, rice with spinach.
stress.[25,26] This study measured whole blood profiles of the sir-
tuin system in women following the consumption of R, RB, RS to
determine whether PGR variation was associated with SIRT sys-
tem profile in each participant as opposed to focusing on acute
Figure 5. Principal component analysis (PCA) biplot and partial least squares (PLS) analyses of UBE2D2 normalized GeXP hSIRTNAD data from human
whole blood at baseline (0 h) and at 30 min, 1 h, 2 h following OGTT ( ), R ( ), RB ( ), and RS ( ). Pre- ( ), peri- ( ), and post-menopausal ( ).
PCA biplot color coded by A) menopausal status and B) meals consumed. Gene expression data positions, denoted by • with the gene symbol placed
next to it (black font), indicate associations with study subjects. The measurements all fall within the Hotelling T2 95% confidence limit. PLS plot of gene
expression data (Y) denoted by • with gene symbol indicated in black font and anthropometric and metabolic markers (X) indicated in gray font coded by
C) menopausal status and D) meals consumed. Skewed data was log-transformed before using in the plots. ABCA1, ATP-binding cassette, sub-family A,
member 1; B/G, baseline glucose; CD38, cyclic ADP-ribose hydrolase 1; chol, cholesterol; F/M, fat mass%; H/C; hip circumference; iAUCg, incremental
area under the curve for glucose responses; iAUCi, incremental area under the curve for insulin responses; NAD, nicotinamide adenine dinucleotide;
NADSYN1, NAD synthetase 1; NAMPT, nicotinamide phosphoribosyltransferase; NAPRT1, nicotinate phosphoribosyltransferase domain containing 1;
NMNAT1, nicotinamide nucleotide adenylyltransferase 1; NMNAT2, nicotinamide nucleotide adenylyltransferase 2; NMNAT3, nicotinamide nucleotide
adenylyltransferase 3; NMRK, nicotinamide riboside kinase; OGTT, oral glucose tolerance test; PARP1, poly (ADP-ribose) polymerase 1; PNP, purine-
nucleoside/orthophosphate ribosyltransferase; PPIB, peptidylprolyl isomerase B (cyclophilin B); PSMB6, proteasome (prosome, macropain) subunit,
beta type, 6; R, rice; RB, rice with bok choy; RS, rice with spinach, QPRT, quinolinate phosphoribosyltransferase; SIRT, sirtuin; TDO2, tryptophan 2,3-
dioxygenase; TRG, triglycerides; UBE2D2, ubiquitin-conjugating enzyme E2D 2; W/C; waist circumference; W:H, waist to hip ratio.
effect of meal interventions. Subsequent analysis of sirtuin gene
expression profiles measured in whole blood samples iden-
tified factors associated with IIV in PGR in VegGI cohort.
PCA analysis indicated sirtuin system gene expression pat-
terns were not ascribed by menopausal status or the meal con-
sumed except for reduced NAMPT in post-menopausal women.
NAMPT is involved in many important biological processes,
including metabolism, stress response, and aging[39] (Figure S2,
Supporting Information). However, gene expression measures
used as input for PCA revealed stratification of the cohort into
two subgroups, designated subgroups A and B. Subgroup A had
higher expression of several sirtuin system gene targets com-
pared to subgroup B. Gene expression profiles characterizing
subgroup A were higher levels of NMRK1, SIRT5, NADSYN1,
NMNAT1, SIRT6, PPIB, SIRT1, SIRT2, ABCA1, SIRT3, NAMPT,
and PARP1 expression, and lower levels of NMRK2 and NM-
NAT2. PLS analysis revealed that the sirtuin gene expression
profiles that distinguish subgroups A and B were associated
with markers linked to metabolic health status. Subgroup A was
associated with a lower basal glucose and insulin and corre-
spondingly lower iAUC for glucose and insulin. These results
are in line with those of previous studies showing that SIRT1
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expression is lower in individuals who are insulin resistant and
glucose intolerant.[40] Previous research from our lab revealed
compromised metabolic status in individuals with low levels of
SIRT1.[25] Notably, SIRT1, SIRT2, and 6, expressed at higher
levels in subgroup A, have been shown to regulate metabolism,
with beneficial effects on glucose metabolism and improved
insulin resistance.[41] Lower postprandial expression levels of
these genes in subgroup B may imply compromised sirtuin
activity. Subgroup B exhibited lower sirtuin system activation,
which was associated with higher PGR, iAUC insulin, plasma
lipid, fat mass and waist/hip circumferences and lower adropin,
independent of menopausal status and test meal consumed.
This is consistent with reports of adropin’s involvement in
preventing insulin resistance and impaired glucose tolerance.[42]
In the VegGI study, a time and meal-dependent postprandial
decrease in plasma adropin was observed. These results agree
with Stevens et al., (2016), who reported significant meal effects
of adropin and a decrease over time compared to baseline
following a mixed meal containing 60% energy as carbohydrate.
However, in the VegGI study, we did not find any consistent
correlation between adropin and PGR. The current study also
identifies a relationship between adropin concentrations, glucose
regulation, andHDL levels in pre-menopausal women. However,
the current analysis was performed on a small sample size of
pre-menopausal women and requires cautious interpretation.
Although epidemiological studies report body composition
as risk factors for metabolic diseases,[38] no correlation between
body composition and PGR was found in the VegGI cohort.
Lack of expected links with metabolic health markers may be
attributed to the “high-risk” participants recruited. Since VegGI
participants all have a BMI > 25, this may be linked to poorer
glycemic control compared to individuals with a “healthy” BMI.
Declining estrogen levels during menopause lead to redistri-
bution of fat from the lower body to abdominal compartments
and are linked to increased T2D and associated risk factors.[38]
However, PGRwas not linked to waist/hip circumference in post-
menopausal women. This may lead to compromised metabolic
health in our cohort of women regardless of menopause status
and lessening differences between pre- and post-menopausal
groups.
Overall, PLS analysis suggests that PGR variation is partly as-
sociated with body composition, adropin and sirtuin system gene
expression. PLS analysis clearly identifies that neither incorpora-
tion of GLV in test meals or menopause status are unequivocal
predictors of PGR. The stratification of the VegGI cohort based
on sirtuin gene expression profiles does identify factors linked to
metabolic health that influence PGR.
Three peri-menopausal womenwere recruited, making it diffi-
cult to draw conclusions for this group. However, metabolic vari-
ability in these women (Figure 5A–D) warrants more research
to comprehend the impact of menopause on glucose regulation
and metabolic health. Nevertheless, menopausal comparisons
were still performed with sufficient numbers in pre- and post-
menopausal women (n = 10 and 18, respectively), as it was con-
sidered appropriate to report all different comparisons.
In conclusion, VegGI study does not support evidence that co-
ingestion of GLV with a carbohydrate meal reduces PGR in the
acute phase. This is not in agreement with epidemiological stud-
ies reporting a potential beneficial effect of high GLV consump-
tion on T2D.[20,21] As hypothesized, there was a high degree of
IIV in PGR, which was not attributed to menopausal status or
the meal consumed. Gene expression profiling in our previous
studies[25] and in VegGI study have proved useful in characteriz-
ing IIV. Sirtuin gene expression profiles identified stratified sub-
groups in the VegGI cohort and associated metabolic and anthro-
pometric markers providing links to differing metabolic health
within the cohort. The study supports links between adropin
and metabolic control, with higher PGR associated with lower
adropin levels. Our findings emphasize the need for improved
study designs, analyses, and reporting of variation in nutrition
studies. Grouping individuals based on criteria assumed to gen-
erate homogenous groups is often overly simplistic and leads
to misreporting of findings and inaccurate interpretations. The
VegGI study demonstrated that gene profiling could prove a use-
ful tool to generate accurate and detailed data on study cohorts.
This may be used to stratify participants and identify associated
metabolic and anthropometric markers to assist in identifying
determinants of variation in nutritional responses. Subgroup-
based approaches based on metabolic phenotype were also re-
cently suggested in order to deal with IIV.[43] Future nutrition
studies should accurately report IIV within study cohorts and fur-
ther investigate the causes of IIV in PGR.
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